Related by context. All words. (Click for frequent words.) 65 Canadian Multicentre Osteoporosis 64 Dubbo Osteoporosis Epidemiology 64 Wisconsin Sleep Cohort 63 Health Initiative Observational 63 Ocular Hypertension Treatment 63 prospective multicentre 62 Osteoporotic Fractures 62 Sherlock uncovering 62 NLSY 62 running Zutphen Elderly 61 Acetonide 61 Bankruptcies soar 61 Early Childhood Longitudinal Study 61 Fragile Families 60 Home Buyer Seller 60 ACCORD Eye 60 Women Ischemia Syndrome 60 Medical Expenditure Panel 60 AVIATION WEEK Workforce 60 multicentre prospective 59 Insulin Resistance Atherosclerosis 59 Current Beneficiary 59 CARDIA 59 Sequenced Treatment Alternatives 59 Ovarian PLCO Cancer 59 Swedish Mammography Cohort 59 Prostate Lung Colorectal 59 Ovarian Cancer Screening 59 Pharmacokinetic PK 59 NAMCS 59 Screening Trial 58 Breakthrough Generations 58 Western Airborne Contaminants 58 Randomized Phase II 58 CALGB 58 Related Conditions NESARC 57 Child Wellbeing 57 Multicenter Phase 57 Midwinter Bald Eagle 57 Young Adults CARDIA 57 Induced polarization IP 57 TMC# C# 57 Prostate Cancer Outcomes 57 Alpha Tocopherol Beta Carotene 57 OPTIMIZE 57 Acute Liver Failure 57 Activity Limitation 57 designated HVTN 57 BCIRG 57 Gore REDUCE Clinical 57 NESARC 57 NCT# ClinicalTrials.gov 57 Therapeutic Effects 57 Alzheimer Disease Cooperative 57 Data Extraction 56 EAT Eating 56 REGARDS 56 segmented regionally 56 INTERMAP 56 Multi Ethnic Study 56 NHANES 56 Investigator Initiated 56 FOREXYARD Daily Forex 56 Prostate Cancer Prevention 56 Prostate AdenoCarcinoma Treatment 56 Childhood Asthma 56 prospective observational cohort 56 REVIVE Diabetes 56 British Gambling Prevalence 56 GLOBOCAN 56 Prospective Randomized 56 Epidemiologic Follow 56 Framingham Offspring 56 ASSERT 56 Relieve Depression STAR 56 Dr. Sara Forhan 56 Multicentre 56 HCV SPRINT 56 Randomized Double blind 56 LUX Lung 56 NO# [002] 56 Medicare Beneficiary 56 #,# surveyors Zagat 56 number NCT# ClinicalTrials.gov 56 MEND CABG 55 CCH Unscheduled Absence 55 Perinatal Mortality 55 Prospective Multicenter 55 PLCO 55 Patient Oriented 55 Car Naturalistic Driving 55 Randomized Controlled 55 Primary Mortgage Servicer 55 proprietary SFD 55 retrospective cohort 55 ANNOUNCES FIRST QUARTER 55 Truvada tablets 55 Debit Issuer 55 Atherosclerosis MESA 55 Replication NCS R 55 multicentre randomized 55 NABE Outlook 55 Birth Cohort 55 Postmenopausal Hormone Therapy 55 Practice Patterns 55 Scandinavian Simvastatin Survival 55 Bayer HealthCare Onyx Pharmaceuticals 55 OUTCOMES 55 Prepaid Customer Satisfaction 55 Birth Defects Prevention 55 ongoing Phase IIIb 55 Medullary Thyroid Cancer 55 NSDUH 55 malignant mesothelioma Alfacell 55 Randomized Phase III 55 Dialysis Outcomes 55 STRATEGY FOR AN OPEN 55 Telephone Omnibus 55 BPM Pulse 55 Ischemic Stroke 55 semistructured interviews 55 Survey MEPS 55 Physician Retention 55 Survey.com 55 NCI Surveillance Epidemiology 55 Hepatitis C Infection 55 Tweet Sentiments web 55 Evaluation WISE 55 Cancer Prevention ATBC 55 Telik Announces 55 Multicenter AIDS 54 NHAMCS 54 LUMINATE 54 Severe Asthma 54 Ischemic Heart Disease 54 Tumor Response 54 Partnership Attitude Tracking 54 See CLINICAL PHARMACOLOGY 54 Randomized Controlled Trials 54 ThermoDox ® clinical 54 SF #v# R 54 Consumption Habits 54 Pluripotent Stem Cells 54 Mississippi Potency Monitoring 54 Nutrition Examination 54 By JENNIFER LEARN 54 Cardiac Allograft Rejection 54 Intervention Trial GAIT 54 Relieve Depression 54 Controlled Trial 54 CARAVAN R 54 Millennium Cohort Study 54 Patient Registry 54 Earned Doctorates 54 multicenter phase 54 Non Alcoholic Steatohepatitis 54 OPT CHF 54 Cohort Consortium 54 CAMMS# 54 Sociodemographic 54 CSAMT MT 54 Cardiotoxicity 54 Analytical Method 54 CAPRIE 54 DSM IV SCID 54 Clinical Outcome 54 Bus Seat Belts 54 Education Next PEPG 54 multiple logistic regression 54 nationally projectable 54 Molecular Genetic 54 Currency Majors Technical 54 Colorectal Screening 54 CALERIE 54 Prevalence Worldwide 54 Alzheimer Disease Genetics 54 Phase IIIb 54 CCCEH 54 Depressive Symptoms 54 GISSI 54 Inflammatory Markers 54 Depression Study TADS 54 STRIDE PD 54 placebo controlled dose escalation 54 dbGaP 54 TAXUS ARRIVE 54 CAS #-#-# Market [001] 54 Cardiac Biomarkers 54 Intervention Trial 54 Prenatal Alcohol 54 Genetic Makeup 54 prospective longitudinal 54 Oral Fingolimod 54 BRIM2 53 Trandolapril 53 ID NCT# 53 JETNET iQ 53 Jack Pirozzolo 53 ONTARGET 53 Multiple Indicator Cluster 53 Vertebral Fracture 53 GPNMB expression 53 Randomized Double Blind 53 Encryption Trends 53 mean ± SEM 53 PRE SURGE 53 Coronary Artery Calcium 53 Aortic Stenosis 53 Schulman Ronca 53 Carotid Revascularization Endarterectomy vs. 53 Avon Longitudinal Study 53 Meta analyzes 53 pexelizumab trials 53 NATIONAL HEALTH 53 RE LY 53 Nation Spending Habits 53 Employee Motivation 53 Datasets 53 QSM Associates software 53 Cultural Cognition 53 Outpatient Setting 53 observational cohort 53 Landmine Impact 53 Gradient Array 53 clinico pathological 53 relapsed MM 53 Multicenter 53 Arch Neurol 53 KN excels 53 CRN Sourcing 53 Maternal Obesity 53 Therapeutic Arthritis 53 Patient Accrual 53 Framingham Offspring Study 53 AVADO 53 Current Controlled Trials 53 Digital Mammographic Imaging 53 exponential regression 53 Airborne geophysical surveys 53 Left Ventricular Dysfunction 53 substudy 53 CHAMPION PCI 53 THE STOCK INDEX 53 Cytogenetic 53 Birth Registry 53 Nationwide Inpatient Sample 53 Cancer Biomarkers 53 Randomized Evaluation 53 multicentre randomized double 53 WHEL 53 Clinical Antipsychotic Trials 53 Gastric Cancer 53 Noncritical 53 Study ARIC 53 Gynecologic Oncology Group 53 Infarct 53 National Epidemiologic Survey 53 NHANES III 53 Celecoxib APC trial 53 Rigorous scientific 53 ICON7 53 Bogalusa Heart 53 COMBINE Study 53 Household Panel 53 HYVET 53 EURIDIS 53 Cancer Incidence Mortality 53 WORKING WELL 53 registrational Phase 53 LIST OF FIGURES 53 TITLE Auctions 53 HRA NCA 53 IMPROVE HF 53 CARAVAN ® 53 CARE HF 53 RECORD1 53 Memory Study WHIMS 53 Sorafenib HCC Assessment 52 Screening Trial DMIST 52 BRFSS 52 YOUR LOCAL ANIMAL SHELTER 52 Prostate Disease 52 PCI ExTRACT TIMI 52 Asthma Intervention 52 Mol Med 52 MADIT II 52 Edge STudy 52 Poisson regression 52 Tor Bjerkedal report 52 Longitudinal Alcohol Epidemiologic 52 Pharmacodynamic 52 Lowering Blood Pressure 52 Insulin Sensitivity 52 SF #v# 52 Educational Longitudinal Study 52 Diabetic Foot Ulcer 52 Coronary Artery Risk 52 WHIMS 52 CABANA 52 NEW PLANT 52 Cholesterol Levels SPARCL 52 Pooled Analysis 52 Anti CD# Antibody 52 INTRODUCTION I. 52 SORT OUT 52 ConclusionThis 52 CPS ASEC 52 Bucuvalas Inc. 52 Biological Effects 52 CATIE AD 52 Natural Catastrophe Stress 52 Lymphocytic 52 Protein Structures 52 Sentinel Lymph Node 52 Normative Aging Study 52 APPRAISE 52 Quality Indicators 52 Population Demographics 52 SCK difficulty 52 meta regression 52 Marine Life CoML 52 Rilonacept 52 multicenter placebo controlled 52 Gene Variation 52 HORIZONS AMI trial 52 Deba Prasad Dash 52 Prognostic Factors 52 J Immunol 52 treatment naive genotype 52 EBMT criteria 52 Antifungals 52 AREDS 52 INSPIRE Trial Phase III 52 Antipsychotic Drug 52 Leukemias 52 KUNC Entertainment 52 BTM UBSW Weekly 52 Vulnerable Plaque 52 METHODOLOGY 52 ASSESS 52 By FilmStew Staff 52 Multivariate logistic regression 52 CURRENT OASIS 7 52 ExTRACT TIMI 52 Survey Methodology 52 FOR AN OPEN 52 BR.# 52 Dose Ranging 52 ROCKET AF 52 Student Engagement NSSE 52 http:/www.aberdeen.com/link/sponsor.asp?cid=# 52 Orissadiary correspondent 52 Dunedin Multidisciplinary Health 52 longitudinal cohort study 52 observational cohort study 52 Heart Profilers 52 Watchful Waiting 52 Baltimore Longitudinal Study 52 EEO Public File 52 phase IIIb 52 Outcome Sciences 52 NHANES #-# 52 serum leptin 52 Pharmacokinetic 52 By SCOTT RASMUSSEN 52 VADT 52 BRIM3 52 Oral Anticoagulants 52 Cost Avoidance 52 EMPOWER ™ 52 borehole electromagnetic 52 different sweetener saccharin 52 Phase Ib II 52 Nutritional Status 52 multiple linear regression 52 EBRI ICI 52 Psychotic Disorders 52 System BRFSS 52 Descriptive statistics 52 ECASS 52 STEP BD 52 MERIT ES 52 conducted retrospective cohort 51 THAT ARE DIFFICULT TO 51 CHIS 51 II Nutrition Cohort 51 Charles Dullin School 51 User Behavior 51 EQUIP OB 51 CAPACITY trials 51 NGFN 51 CALGB # [002] 51 placebo controlled Phase III 51 MERLIN TIMI 51 Rashmi r Parida 51 National Oncologic PET 51 bapineuzumab AAB 51 Content Outline 51 Observational Studies 51 randomized Phase III 51 HER2 positive metastatic breast 51 EOTC Family Matters 51 ST Segment Elevation 51 Breast Density 51 Systematic Review 51 Biobanks 51 Secondary efficacy endpoints 51 CA BUSINESS 51 DAPT Study 51 INTERPHONE 51 Phase III AFFIRM 51 HPV Vaccine Gardasil 51 blinded randomized placebo controlled 51 Foodborne Diseases Active 51 First Patient Enrolled 51 CARDIA study 51 Genetic Susceptibility 51 Atherosclerosis Risk 51 ORACLE MS 51 SIMPADICO 51 CYT# potent vascular disrupting 51 Kaplan Meier analysis 51 Secondhand Smoke Exposure 51 National Inpatient Sample 51 NestWatch 51 randomized controlled Phase 51 ALSPAC 51 DEPLOY 51 Genetic Variation 51 NTRA Thoroughbred Facts 51 Hormone Receptor Positive 51 AVOREN 51 BOLDER II 51 Functional Outcomes 51 PRESEPT 51 EUROCARE 51 Stenting Trial 51 WMU 5D 51 coronary revascularizations 51 Stent Thrombosis 51 Nonalcoholic fatty liver 51 controlled dose escalation 51 Doug Roy MASc 51 Intervention Effectiveness 51 Postnatal Depression 51 initiate multicenter 51 prospective randomized multicenter 51 AIM HIGH 51 Acute Coronary Syndromes 51 Healthy Behaviors 51 multicenter randomized controlled 51 SPATIAL 51 -0 Content Outline 51 Adverse Event 51 Male Ageing 51 Prevalence Estimates 51 Trial PCPT 51 EXPENSES Employee Compensation 51 pharmacokinetic PK 51 #:#-#,# CrossRef Medline [001] 51 Membrane Separation Technologies 51 Venous Thrombosis 51 User Element 51 subgroup analyzes 51 ISPO institute 51 prospective observational 51 SWOG 51 Skin Lesions 51 HEALTHY LIFE 51 GYTS 51 exploratory endpoints 51 Glioma 51 CONDOR 51 MarketTools ensures 51 Transgender Discrimination 51 ABCSG 51 ANNOUNCES ANNUAL 51 Prognostic Significance 51 Children ALSPAC 51 Biophysical# 51 Broiler Chick Placements 51 Double Blind Placebo 51 Usage Monitoring 51 SRBI 51 Diamyd Medical Diamyd 51 Thomson Reuters PULSE 51 Silicone Breast Implant 51 double blinded randomized 51 Lymphoma Patients 51 Passive Smoking 51 Complications Trial 51 Outcome Measures 51 Phase III randomized placebo 51 anti JCV antibodies 51 Hematological Cancers 51 Formative Assessment 51 Nutrition Examination Surveys NHANES 51 Hospitalized Patients 51 haplotype map 51 Kids Inpatient Database 51 prospective randomized placebo 51 Col. Ralph Kauzlarich 51 Randomized Trials 51 cross tabulations 51 Topline Results 51 R# #mg BID 51 Patient Outcomes 51 Inhaled Nitric Oxide 51 CARTaGENE 51 Nonclinical 51 Randomized trials 51 actigraphy 51 Therapeutic Efficacy 51 REVIVE 51 By BHSN.com Staff 51 Antidepressant Use 51 EchoCRT 51 multicenter multinational 50 Medication Error 50 digit dial RDD 50 Negative Symptoms 50 Glucosamine chondroitin Arthritis 50 Cosmic Evolution 50 limiting generalizability 50 IBR Staff 50 Gene Ontology 50 brown baggers #x# 50 serum lipid levels 50 Ranolazine 50 Study Evaluating 50 prospective observational studies 50 Cancer Genetic Markers 50 Clinical Evaluation 50 Demographic Analysis 50 Clinical Guideline 50 #:#-#,# CrossRef Medline [002] 50 Pre Exposure Prophylaxis 50 Radiation Therapy Oncology 50 ENESTnd 50 lake sediment geochemical 50 Stem Cell Transplants 50 Tpull Weekly Marvel Comics 50 Comparative Effectiveness 50 Immunomedics Announces 50 Intervention Effectiveness CATIE 50 ASPIRE HIGHER 50 Radiation Induced 50 Phase Ib clinical 50 www.ncoa.org 50 MegaPanel 50 Paleobiology Database 50 Nesiritide 50 prospectively defined 50 Prognostic Value 50 Therapeutic Intervention 50 enzyme immunoassay EIA 50 Tumor Sequencing Project 50 INTERHEART study 50 lorcaserin Phase 50 digit dialed 50 #F FDG PET 50 Heart Failure Therapies 50 multinational multicenter randomized 50 bepotastine besilate nasal spray 50 Electroencephalography 50 Horizon Scanning 50 Ebola Vaccine 50 Sexual Victimization 50 TECHNOLOGIST 50 Worksite Sales 50 MIVI TRUST 50 Premature Deaths 50 TONYA S. 50 Synovate eNation 50 THIS STUDY 50 Spatio Temporal 50 pollster Taloustutkimus 50 Finsat GCE 50 Cognitive Function 50 EBRI Issue Brief 50 Induced polarization 50 prospective cohort 50 Genetic Markers 50 Lung Injury 50 p# biomarker 50 Usability Testing 50 Cause Mortality 50 ORAL Solo 50 PRoFESS 50 subanalysis 50 Pre RELAX AHF 50 UPGRADE TO 50 Aggressive Reduction 50 inferential statistics 50 Lung Cancer Screening 50 International Verapamil SR 50 InRule Technology ® 50 Exelixis XL# 50 Kidney Int 50 Risk Longitudinal 50 SPARCL 50 Cancer Incidence 50 crizotinib PF # 50 noninstitutionalized 50 Long Lesion 50 Abiraterone Acetate 50 Novarica ACE Ranking 50 Tristate AM 50 Brain Wiring 50 Index SPI SPIEX 50 simplex virus 50 Cosmetic Surgery Procedures 50 QualityMetric 50 Coronary Revascularization 50 Genetic Defect 50 ANCOVA 50 Nightly Crime 50 Subarachnoid hemorrhage 50 CONSULTATION ON 50 Echocardiographic 50 bile acid metabolism 50 Non Melanoma Skin 50 nonrandomized 50 Laryngeal Cancer 50 aldosterone antagonist 50 Nymox NX 50 Neanderthal Genome Project 50 INFORMATION SYSTEMS 50 Long beaked Echidna 50 BLEND OF 50 visit http:/www.harrispollonline.com 50 Sudha Seshadri MD 50 Confocal Microscopy 50 Observational studies 50 APTIVUS 50 Subgroup Analysis 50 ARCALYST ® rilonacept 50 bought Glaxo Serevent 50 transcranial Doppler ultrasound 50 Initiated Phase 50 Disciple Bible 50 Nonalcoholic Steatohepatitis 50 Histologic 50 Drug Prevents 50 TRANSFORMS 50 Entereg TM 50 Treatment Diabetic Retinopathy 50 Acute Decompensated Heart Failure 50 Envisat satellites 50 differential gene expression 50 Multicenter Trial 50 Prostate Cancer Clinical Trial 50 Neurologic Disorders 50 geological mapping trenching 50 Interview Survey CHIS 50 Spine Patient Outcomes 50 precaution Wiehle 50 NSABP 50 Urgent Intervention Triage 50 = Per [007] 50 Mussel Watch 50 Pulmonary Arterial Hypertension 50 controlled multicenter 50 TFT LCD Panels 50 European Randomized Study 50 ASTEROID 50 UNLOAD 50 Vietnam Veterans Readjustment 50 HDR Decision Economics 50 Chronic Obstructive Lung 50 Anceta 50 multicenter randomized clinical 50 J Rheumatol 50 Gartner WCM 50 spirometric 50 EXPLORE Xa 50 Pregnancy Outcomes 50 Chronic Heart Failure 50 Sequencing Systems 50 Chronic HCV 50 Roughrider Uranium Deposit 50 Study ADCS 50 ENVISION 50 Communities ARIC study 50 atherothrombotic disease 50 Lipid Lowering Treatment 50 Comorbidities 50 Constructive criticism passionate 50 SWiTCH 50 Cognitive Impairment 50 Kaplan Meier method 50 EVALUATIONS 50 APEX AMI trial 50 Bayley Scales 50 Statistical Genetics 50 Ambulatory Medical 50 FIES 50 Aplidin R 50 Cost Estimating 50 Ekahau Site Survey 50 Giving Volunteering 50 FASEB J. 50 IMPACT IMmunotherapy 50 Supplementary Homicide 50 MEASURE DHS 50 Female Sexual Function 50 variograms 50 ANOTHER MAJOR 50 Alternative Powertrain 50 Peter Possing Andersen Signe 50 Nicotine Vaccine 50 Stop Hypertension DASH 49 Room Dining Room 49 linear regression analyzes 49 Abdominal Fat 49 Phase Ib Clinical Trial 49 Mobile Metal Ions 49 Nephrol Dial Transplant 49 Diabet Med 49 #,# WeddingWire newlyweds 49 IPA SBRB 49 KRAS gene mutations 49 DGGS 49 ELCAP 49 CLL8 49 Comorbidity 49 mailed questionnaires 49 HCUP 49 Evaluation Tool 49 Respiratory Distress 49 REL CFO 49 prospective nonrandomized 49 Brucejack Area 49 RE LY ® 49 Pivotal Phase 49 Double Blind Randomized 49 Investigational Agent 49 CAHPS 49 Long Term Efficacy 49 Meta Analysis 49 AVERROES 49 Index VNI Forecast 49 lithogeochemical samples 49 WorldatWork Salary Budget 49 Physician Compensation 49 Septic Shock 49 Multicenter Automatic Defibrillator Implantation 49 Koncept Analytics 49 Minimally Invasive Treatment 49 Predictive Toxicology 49 NLSS 49 evaluating mipomersen 49 RE MODEL 49 shatters myths 49 Postsecondary Student 49 REVIVE TA 49 prelicensure 49 FIVE FORCES ANALYSIS 49 Folic Acid Supplements 49 multivariate logistic regression 49 AND RECOMMENDATIONS 49 www.oversightsystems.com 49 Prospective Cohort Study 49 Thrombolysis 49 Consumer Preferences 49 Glucose Monitoring 49 Osteoarthritis Patients 49 AIR2 Trial 49 Racial Attitudes 49 GAMMAGARD 49 Clinicaltrials.gov 49 Reveals Significant 49 Climate Modeling 49 Diagnostic Criteria 49 PROGRAM COORDINATOR 49 Lung Cancer Risk 49 Simin Nikbin Meydani 49 NSABP B 49 dietary questionnaires 49 #:#-#,# CrossRef 49 Sipuleucel T 49 Prostate Biopsy 49 Nicotine Addiction 49 COMPARE 49 Psychiatric Epidemiology 49 Prostate Cancer Survival 49 Longitudinal studies 49 COU AA 49 DIAGNOSTIC 49 Growth Hormone Deficiency 49 Termed Massively Parallel 49 End Results SEER 49 NELS 49 PREVAIL 49 Recurrent Breast Cancer 49 genomewide 49 Ethnicity Race 49 BY WILLA J. 49 #:#-# Abstract Free [009] 49 Venous Thromboembolism 49 LLRI 49 Phase III multicenter 49 Landsat imagery 49 Ovarian Cancers 49 geophysics trenching 49 Attributed equity 49 pharmacokinetic pharmacodynamic 49 formal pharmacokinetic PK 49 Hospitalization Rates 49 Nonalcoholic Fatty Liver Disease 49 AMCAT 49 Sleep Disturbances 49 Multiple Myeloma Patients 49 myocardial viability 49 EXECUTIVE SUMMARY 49 iPrEx study 49 logistic regression analyzes 49 microalbumin 49 placebo controlled Phase 49 Invasive Pneumococcal Disease 49 Acute Myocardial Infarction 49 Hematological 49 Obese Teens 49 Breeding Bird Survey 49 Breast Ovarian Cancer 49 CYP#A# CYP#D# 49 Premature Births 49 Screening Mammography 49 CaPSURE 49 Solar Geophysical Activity 49 congenital toxoplasmosis 49 Geosensing 49 HPA Consultants 49 Thomson Reuters MarketScan 49 GVAX Pancreas Vaccine 49 WOSCOPS 49 multicenter prospective 49 prospective multicenter 49 bazedoxifene conjugated estrogens 49 Associates Vehicle Dependability 49 Tables Charts 49 Dr. Amytis Towfighi neurology 49 digit dialing RDD 49 multivariate Cox 49 IMPACT DCM 49 variant rs# 49 Malignant Glioma 49 randomized controlled multicenter 49 Aggressive Prostate Cancer 49 Dietary Modification Trial 49 www.sanbolic.com 49 Health Examination Survey 49 Child Behavior Checklist 49 multivariable Cox 49 Genetic Predisposition 49 phosphorylated tau 49 Adjuvant Chemotherapy 49 Diabetes Complications 49 Multiple logistic regression 49 JD Power Vehicle Dependability 49 See WARNINGS 49 Fecal Incontinence 49 Genetic Diversity 49 Repeatable Battery 49 Hired Brains 49 Stroke REGARDS study 49 BLOSSOM 49 Netherlands Cohort Study 49 Advaxis Phase 49 GetGoal Phase III 49 ImmuKnow assay 49 Diabetes Interventions 49 Systolic Hypertension 49 Stable Angina 49 Endovascular Valve Edge 49 Breast Cancer Stem Cells 49 Preclinical Models 49 entitled Treatment Algorithms 49 Individualized Learning 49 BEXXAR Therapeutic Regimen 49 Genotypes 49 VAMCs 49 NCDB 49 fasting serum 49 Geographies covered 49 PD2i R 49 RELATE 49 Prostate Screening 49 Patient Populations 49 Cardiac Resynchronization 49 Treatment Outcome 49 Human Hookworm Vaccine Initiative 49 pole dipole 49 Hepatotoxicity 49 Nielsen Claritas 49 RELEASE FROM 49 HAMMOND HM Offense 49 Skin sterol 49 ug dose 49 MMR Vaccine 49 Sidec 49 PIRE 49 Aggressive Behavior 49 Globocan 49 OSV Newbuild Program 49 gamma spectrometry 49 Prevent Child 49 SEER database 49 comparative genomic 49 TITLE File Inclusion 49 Child Mortality 49 Gender Differences 49 Decadal 49 sociodemographic characteristics 49 metapopulation 49 EDICT 49 CUTTING DOWN 49 internalizing disorders 49 Bone Metastases 49 Demonstrates Sustained 49 Antihypertensive 49 CONTRIBUTE TO THE 49 Epidemiologic Catchment Area 49 Risk Behavior 49 PORxin TM platforms 49 Cognitive Aging 49 Glucosamine Chondroitin Arthritis 49 complement inhibitor eculizumab 49 SELECTED STATISTICAL INFORMATION 49 Peripheral Blood 49 TARGIT 49 National Longitudinal Survey 49 Diagnostic Tools 49 kidney urologic 49 RasmussenReports.com 49 landmark ATHENA 49 PNH Registry 49 APPRAISAL 49 Adverse Outcomes 49 ExCell study 49 Combination Treatment 49 Hip Fracture Risk 49 Randomized Placebo Controlled 49 MULLIGAN FAMILY FUN CENTER 49 Study PATS 49 metastatic neuroendocrine tumors 49 Randomized Clinical Trial 49 Organisational Change 49 Lipstick Mystic Love 49 HPTN 49 AIR CF2 49 Rakai Uganda 49 Chemotherapeutic Agents 49 Multicenter Randomized 48 DOI #.# 48 COPERNICUS 48 Estrogen Therapy 48 sunitinib malate 48 Pneumococcal vaccines 48 Kaiser Permanente Vaccine 48 APCO Insight 48 ambivalent networkers 48 STICH trial 48 Eye Diseases 48 ICSI cycles 48 HCV Protease Inhibitor 48 Radiation Exposure 48 Anthropometric 48 intravesical infusion therapy 48 Bucuvalas 48 Yikyung Park 48 multicenter randomized double 48 Val HeFT 48 Metabolomic 48 Pervasive Developmental Disorders 48 Uterine Cancer 48 Ventricular Arrhythmias 48 Interpersonal Psychotherapy 48 BLOOM Behavioral modification 48 Broadband Subscriber 48 elevated triglycerides 48 Phase 2b Clinical Trial 48 LAB CGRP 48 Psychometric tests 48 Cardiovascular Risk Factors 48 Enzastaurin 48 STEALTH C 48 Ameris Bancorp Reports 48 Learning Experiences 48 Unmet Medical 48 Summative 48 sociodemographic 48 EPTA examines employee 48 Related Mortality 48 Breast Cancer Recurrence 48 Guideline Update 48 Light Olefins 48 Epigenome 48 Epidemiological Studies